Pyrazine

Pyrazine

SCHEMBL22491600

C1=COc2ccccc2O1.c1cnccn1

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.38
LMNA P02545 3/20 0.35
CRHBP P24387 2/20 0.35
CRHR2 Q13324 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MAOB P27338 2/20 0.35
MAOA P21397 1/20 0.35
HTT P42858 1/20 0.35
ABCG2 Q9UNQ0 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
ATAD2 Q6PL18 1/20 0.33
ITGB2 P05107 1/20 0.33
ICAM1 P05362 1/20 0.33
ITGAL P20701 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
MAPT P10636 1/20 0.32
MEN1 O00255 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30334802 0.85 LMNA (0.43) LMNACRHBPCRHR2SMN1; SMN2MAOB
SCHEMBL121647 0.85 LMNA (0.43) LMNACRHBPCRHR2SMN1; SMN2MAOB
Hydrochloric Acid SCHEMBL11520836 0.82 LMNA (0.41) LMNACRHBPCRHR2SMN1; SMN2MAOB
Cyclohexane SCHEMBL23674790 0.77 SMN1; SMN2 (0.43) LMNACRHBPCRHR2SMN1; SMN2MAOB
Dioxane SCHEMBL23674718 0.74 LMNA (0.62) LMNACRHBPCRHR2SMN1; SMN2MAOB
SCHEMBL20483066 0.72 LMNA (0.31) LMNACRHBPCRHR2SMN1; SMN2HTT
Pyrazine SCHEMBL22491477 0.70 ABCG2 (0.74) LMNACRHBPCRHR2SMN1; SMN2MAOB
Hydrochloric Acid SCHEMBL1653598 0.69 AOC1 (0.31)
SCHEMBL32690528 0.67 LMNA (0.31) LMNACRHBPCRHR2SMN1; SMN2HTT
SCHEMBL29568932 0.67 CA12 (0.38) LMNASMN1; SMN2HTTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3331525-B1 USE OF CRAC CHANNEL INHIBITORS FOR THE TREATMENT OF STROKE AND TRAUMATIC BRAIN INJURY CALCIMEDICA INC (US) 2020-10-07 EP disclosed